Cardinal Looks Ahead To A New Decade For US Biosimilars

Cardinal Health’s Dracey Poore Talks Uptake, Interchangeability And Education

 
• By Dave Wallace
  
Dracey Poore discusses the road ahead for US biosimilars (Shutterstock)

More from Interviews

More from Policy & Regulation